These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30269406)

  • 1. The Linked Clinical Trials initiative (LCT) for Parkinson's disease.
    Brundin P; Wyse RK
    Eur J Neurosci; 2019 Feb; 49(3):307-315. PubMed ID: 30269406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials Initiative.
    Wyse RK; Isaacs T; Barker RA; Cookson MR; Dawson TM; Devos D; Dexter DT; Duffen J; Federoff H; Fiske B; Foltynie T; Fox S; Greenamyre JT; Kieburtz K; Kordower JH; Krainc D; Matthews H; Moore DJ; Mursaleen L; Schwarzschild MA; Stott SRW; Sulzer D; Svenningsson P; Tanner CM; Carroll C; Simon DK; Brundin P
    J Parkinsons Dis; 2024; 14(4):657-666. PubMed ID: 38578902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Advances in Drug Repurposing for Parkinson's Disease.
    Chen X; Gumina G; Virga KG
    Curr Med Chem; 2019; 26(28):5340-5362. PubMed ID: 30027839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned.
    Hung AY; Schwarzschild MA
    Neurotherapeutics; 2020 Oct; 17(4):1393-1405. PubMed ID: 33205384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience.
    Foltynie T; Athauda D
    Prog Brain Res; 2020; 252():493-523. PubMed ID: 32247373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments.
    Brundin P; Barker RA; Conn PJ; Dawson TM; Kieburtz K; Lees AJ; Schwarzschild MA; Tanner CM; Isaacs T; Duffen J; Matthews H; Wyse RK
    J Parkinsons Dis; 2013 Jan; 3(3):231-9. PubMed ID: 24018336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease.
    Bortolanza M; Nascimento GC; Socias SB; Ploper D; Chehín RN; Raisman-Vozari R; Del-Bel E
    J Neural Transm (Vienna); 2018 Oct; 125(10):1403-1415. PubMed ID: 30109452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Old wines in new bottles: Repurposing opportunities for Parkinson's disease.
    Kakkar AK; Singh H; Medhi B
    Eur J Pharmacol; 2018 Jul; 830():115-127. PubMed ID: 29689247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug repurposing strategies of relevance for Parkinson's disease.
    Fletcher EJR; Kaminski T; Williams G; Duty S
    Pharmacol Res Perspect; 2021 Aug; 9(4):e00841. PubMed ID: 34309236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repositioning of drugs for Parkinson's disease and pharmaceutical nanotechnology tools for their optimization.
    Hernández-Parra H; Cortés H; Avalos-Fuentes JA; Del Prado-Audelo M; Florán B; Leyva-Gómez G; Sharifi-Rad J; Cho WC
    J Nanobiotechnology; 2022 Sep; 20(1):413. PubMed ID: 36109747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease.
    Bourque M; Morissette M; Di Paolo T
    Neuropharmacology; 2019 Mar; 147():37-54. PubMed ID: 29649433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-Abl Inhibition; A Novel Therapeutic Target for Parkinson's Disease.
    Abushouk AI; Negida A; Elshenawy RA; Zein H; Hammad AM; Menshawy A; Mohamed WMY
    CNS Neurol Disord Drug Targets; 2018 Apr; 17(1):14-21. PubMed ID: 28571531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of Repurposing Drugs and Identifying Contraindications from Real World Study in Parkinson's Disease.
    Tang Y; Yang K; Zhao J; Liang X; Wang J
    ACS Chem Neurosci; 2019 Feb; 10(2):954-963. PubMed ID: 30702853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease.
    Johnston TH; Lacoste AMB; Visanji NP; Lang AE; Fox SH; Brotchie JM
    Neuropharmacology; 2019 Mar; 147():11-27. PubMed ID: 29907424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Lees AJ; Tolosa E; Olanow CW
    Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease-Modifying Drugs in Parkinson's Disease.
    Park A; Stacy M
    Drugs; 2015 Dec; 75(18):2065-71. PubMed ID: 26581672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies.
    Broadstock M; Ballard C; Corbett A
    Expert Opin Pharmacother; 2014 Sep; 15(13):1797-810. PubMed ID: 24992196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease.
    Athauda D; Foltynie T
    Neuropharmacology; 2018 Jul; 136(Pt B):260-270. PubMed ID: 28927992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How should future clinical trials be designed in the search for disease-modifying therapies for Parkinson's disease?
    Lenka A; Jankovic J
    Expert Rev Neurother; 2023 Feb; 23(2):107-122. PubMed ID: 36803618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repositioning drugs by targeting network modules: a Parkinson's disease case study.
    Yue Z; Arora I; Zhang EY; Laufer V; Bridges SL; Chen JY
    BMC Bioinformatics; 2017 Dec; 18(Suppl 14):532. PubMed ID: 29297292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.